» Articles » PMID: 37719791

Prevalence of Hepatitis B Infection in the Gambian Population: A Narrative Review of Recent Developments

Overview
Journal Prev Med Rep
Date 2023 Sep 18
PMID 37719791
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis B is a "silent epidemic", fifty to a hundred (50-100) times more infectious than HIV, a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). HBV can cause acute and chronic infection and subsequently results in a high risk of death from cirrhosis and liver cancer. Despite the availability of a safe and effective vaccine, HBV continues to be a global burden including in The Gambia. This study reviewed the recent trends in the epidemiological characteristics of HBV in the Gambia. The researchers conducted an online literature search for primary studies on HBV prevalence published in the past two decades from Jan 1992 to Feb 2022 inclusive on Google Scholar, PubMed, and Scopus. All retrieved studies were assessed for eligibility according to specific inclusion/exclusion criteria, data completeness, and methodological coherence. We found that HBV infection prevalence is above 8% in The Gambia. Moreover, HBV is the most common cause of hepatocellular carcinoma (HCC) in Gambia. Liver cirrhosis and HCC have the highest mortality contribution among hepatitis patients, with occult HBV carriers as major culprits. Also, vaccination coverage has declined from 91% to 88% according to reports from current literature. To achieve the WHO goal of eliminating HBV by 2030, policies targeting infection transmission control among risk groups, community awareness programs, research, price reduction of drugs, mass vaccinations, and diagnostics should be urgently instituted.

Citing Articles

Updates on Hepatitis B Virus (HBV) Infection 2.0.

Chemin I, Pujol F Microorganisms. 2023; 11(12).

PMID: 38138018 PMC: 10746071. DOI: 10.3390/microorganisms11122874.

References
1.
Fortuin M, Chotard J, Jack A, Maine N, Mendy M, Hall A . Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet. 1993; 341(8853):1129-31. DOI: 10.1016/0140-6736(93)93137-p. View

2.
Slavin R . Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol. 1995; 48(1):9-18. DOI: 10.1016/0895-4356(94)00097-a. View

3.
Makvandi M . Update on occult hepatitis B virus infection. World J Gastroenterol. 2016; 22(39):8720-8734. PMC: 5075547. DOI: 10.3748/wjg.v22.i39.8720. View

4.
Bittaye M, Idoko P, Ekele B, Obed S, Nyan O . Hepatitis B virus sero-prevalence amongst pregnant women in the Gambia. BMC Infect Dis. 2019; 19(1):259. PMC: 6419830. DOI: 10.1186/s12879-019-3883-9. View

5.
Viviani S, Jack A, Hall A, Maine N, Mendy M, Montesano R . Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine. 1999; 17(23-24):2946-50. DOI: 10.1016/s0264-410x(99)00178-4. View